Crispr Therapeutics AG (CRSP) is around the top of the Biotechnology industry according to InvestorsObserver. CRSP received an overall rating of 56, which means that it scores higher than 56 percent of all stocks. Crispr Therapeutics AG also achieved a score of 69 in the Biotechnology industry, putting it above 69 percent of Biotechnology stocks. Biotechnology is ranked 35 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is trading at $141.80 as of 3:01 PM on Thursday, Dec 3, a rise of $10.26, or 7.8% from the previous closing price of $131.54. The stock has traded between $130.35 and $147.82 so far today. Volume today is more active than usual. So far 1,323,678 shares have traded compared to average volume of 1,022,719 shares.
Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.
